Changping Laboratory Brain Network Breakthrough: SCAN Identified as Core Pathology in Parkinson's Disease – Nature Study

Understanding the Changping Laboratory Brain Network Breakthrough

The recent publication in Nature marks a pivotal moment in neuroscience, where researchers from Beijing's Changping Laboratory, led by Professor Hesheng Liu, have pinpointed the somato-cognitive action network (SCAN)—a specific brain circuit—as the underlying pathological mechanism driving Parkinson's disease (PD). This discovery reframes PD not merely as a motor disorder but as a comprehensive disruption in the brain's action command center, linking cognition, motivation, and movement.809

Parkinson's disease affects millions globally, with over 10 million cases worldwide, characterized by symptoms like tremors, bradykinesia (slowed movement), rigidity, and non-motor issues such as cognitive decline and sleep disturbances. Traditional views centered on dopamine loss in the substantia nigra (SN), a deep brain structure. However, this new research reveals that hyperconnectivity—excessive neural signaling—within the SCAN network between cortical and subcortical regions is the core issue.80

SCAN resides in the primary motor cortex (M1), alternating like piano keys between regions controlling specific body parts (effectors like hand, foot, mouth). It integrates arousal, organ physiology, behavioral motivation, and whole-body motor plans, explaining PD's diverse symptoms from initial sleep issues to advanced cognitive impairments.

Decoding the Somato-Cognitive Action Network (SCAN)

The somato-cognitive action network (SCAN), first described in 2023 by collaborators including Washington University researchers, is a functional network embedded in M1. Unlike effector-specific zones, SCAN coordinates higher-order processes: turning thoughts into actions while regulating internal states like heart rate and alertness.780

In healthy brains, subcortical hubs like the SN, subthalamic nucleus (STN), globus pallidus internus (GPi), ventral intermediate nucleus/centromedian (VIM/CM), globus pallidus externus (GPe), and putamen connect preferentially to SCAN over effectors. The study analyzed resting-state functional connectivity (RSFC) from 863 participants, confirming this selective linkage (all paired t-tests >9.8, P < 0.0001, FDR-corrected).80

In PD patients, SCAN exhibits pathological hyperconnectivity with these subcortical nodes (t=3.2–3.5, P=0.001–0.002), absent in controls or other disorders like essential tremor (ET), dystonia, or ALS. This overload disrupts signal processing, manifesting as PD hallmarks and correlating with severity scores like MDS-UPDRS-III (r=0.162, P=0.037).80

Changping Laboratory: A Hub for Chinese Neuroscience Innovation

Established in Beijing's Changping District, Changping Laboratory (CPL) is a state-of-the-art facility driving life sciences research, particularly in brain connectomics and neuromodulation. Led by pioneers like Hesheng Liu, affiliated with Peking University (PKU) and Tsinghua University, CPL fosters interdisciplinary collaborations.2447

Liu's team spearheaded the Chinese Human Connectome Project (CHCP), mapping brain networks with unprecedented precision. This Nature paper builds on prior work, integrating data from PKU, Tsinghua, Henan Provincial People’s Hospital, and international partners like Washington University and Harvard.Learn more about CPL's neuroscience efforts.80

For aspiring researchers, CPL exemplifies China's investment in higher education and R&D, offering opportunities in brain imaging and clinical translation. Explore research jobs in neuroscience or academic positions in China to contribute to such breakthroughs.

Rigorous Methods Powering the Discovery

The study amassed a multimodal dataset from 863 individuals across 11 cohorts, using 3T MRI scanners for high-resolution rsfMRI (voxel sizes 2.2–3 mm). Key datasets included 166 PD patients (PIPD), 342 DBS cases, 36 TMS patients, and controls.80

• RSFC analysis: Seed-based Pearson correlations from subcortical ROIs to cortical networks, z-transformed.
• Personalized mapping: Iterative precision functional parcellation into 17 networks, winner-takes-all subcortical assignment.
• Therapy tracking: Longitudinal fMRI pre/post-DBS/TMS, linear mixed-effects (LME) models for UPDRS-III changes.
• Statistics: FDR-corrected t-tests, permutations for ECoG potentials, Spearman correlations for targeting efficacy.

Code and data are openly available on GitHub and repositories, enabling reproducibility.Read the full Nature paper.80

Hyperconnectivity: Unraveling PD's Neural Signature

PD brains show expanded SCAN territory in subcortex (χ² P < 0.001, FDR), with elevated RSFC (e.g., SN-SCAN t=3.5, P<0.001). This specificity distinguishes PD from mimics, correlating with motor (UPDRS-III), cognitive (MMSE r=0.161), and mood scores (HAMA r=-0.186).80

Levodopa acutely normalizes hyperconnectivity (t=3.58, P=0.001), linking dopamine to circuit function. DBS sweet spots (74.3% VTA overlap) align with SCAN nodes, with evoked potentials stronger in SCAN (t=5.7, P=1.33×10⁻⁶).80

Transformative Therapies Targeting SCAN

Effective interventions reduce SCAN hyperconnectivity:

• Deep Brain Stimulation (DBS): STN/GPi/VIM targets overlap SCAN; post-op UPDRS-III drops (LME F=15.71, P<0.0001), hyperconnectivity normalizes (F=4.25, P=0.006).
• Transcranial Magnetic Stimulation (TMS): SCAN-targeted intermittent theta-burst (iTBS) doubles efficacy vs. effector sites (week 2 Δ=-6.57, P=0.0003; interaction P<0.001).
• MR-guided Focused Ultrasound (MRgFUS): Proximity to thalamic SCAN hotspot predicts improvement (ρ=-0.68, P=0.031).

A novel non-invasive system from the team achieved 55.5% efficacy in two weeks.78 For clinicians and researchers, this shifts paradigms toward circuit-specific neuromodulation.

Clinical Outcomes and Real-World Impact

In TMS trials (n=36), SCAN targeting accelerated relief in bradykinesia, rigidity, tremor, and axial symptoms (all P<0.05). DBS longitudinal data (up to 24 months) showed sustained benefits correlating with connectivity changes (F=6.86, P=0.013).80

China's aging population (projected 400 million over 60 by 2035) amplifies PD's burden; this offers scalable, personalized options. SCAN RSFC could serve as a biomarker for early diagnosis and therapy selection.

Global Collaborations Elevating Chinese Research

Joint efforts with Washington University (Nico Dosenbach), Harvard, UCSF, and Chinese universities underscore international synergy. Tsinghua's neuromodulation center and PKU's brain institute provided expertise in engineering and imaging.80

Such partnerships boost China's higher education profile, attracting global talent. Aspiring professors can find professor jobs or faculty positions in neuroscience at top institutions.

Implications for Higher Education and Careers

This breakthrough highlights neuroscience's growth in China, with labs like CPL training PhDs and postdocs. It opens doors in precision medicine, AI-driven imaging, and clinical trials. Students and professionals should pursue advanced degrees; resources like academic CV tips aid applications.

Stakeholders—from policymakers funding brain initiatives to educators integrating connectomics—benefit. Explore postdoc opportunities or research assistant roles to join the frontier.

Future Outlook: Personalizing PD Treatment

Prospects include ultra-high-field MRI for precise SCAN mapping, closed-loop DBS, and cortical stimulation hybrids. Multicenter TMS trials and SCAN-specific drugs loom large. Liu envisions "circuit disorders" guiding therapies across brain diseases.78

For academics, this fuels grants and collaborations. Stay informed via university rankings and career advice. Engage with professors on Rate My Professor, search higher ed jobs, or access career advice.